Evidence map›Paper›PMID 22355790›Full record

ArticleScientific reports2012

A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals.

Hisashi Moriguchi, Yue Zhang, Makoto Mihara, Chifumi Sato

RetractedAbstract readRetracted Publication
In one paragraph

Article in Scientific reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Hisashi Moriguchi
Yue Zhang
Makoto Mihara
Chifumi Sato

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various methods for the direct reprogramming of human somatic cells have been developed. However, a therapeutic method to reprogram and eliminate human solid tumor cells has not been developed. Here we show a novel therapeutic method to reprogram and eliminate human solid tumor cells with chemicals. This therapeutic method may be applicable to various human solid tumor cells that express aldo-keto reductase family 1 member B10 (AKR1B10) and retinoid X receptors (RXRs).

Indexed as

Aldehyde ReductaseAldo-Keto ReductasesCarcinoma, HepatocellularHumansLiver NeoplasmsLiver TransplantationOxygen ConsumptionRetinoidsRetinoid X ReceptorsAKR1B10 protein, humanAldehyde ReductaseAldo-Keto ReductasesRetinoidsRetinoid X Receptors

Identifiers

PMID22355790
PMCPMC3282982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.